Overexpression of MRNA-decapping Enzyme 1a Affects Survival Rate in Colorectal Carcinoma

Overview

Journal Oncol Lett

Specialty Oncology

Date 2018 Jul 3

PMID 29963186

Citations 10

Authors

Chuanqing Wu

Weizhen Liu

Tuo Ruan

Xiaojie Zhu

Kaixiong Tao

Weikang Zhang

Affiliations

Soon will be listed here.

Abstract

Processing bodies (P-bodies) are one of the most well understood types of RNA granules, and are associated with a variety of diseases, including cancer. mRNA-decapping enzyme 1a (DCP1a), which may be used as a marker to analyze P-bodies, participates in the removal of the 5'-methylguanosine cap from eukaryotic mRNAs as a cofactor. The aim of the present study was to analyze the association between DCP1a expression and clinical features in colorectal carcinoma (CRC). The levels of DCP1a mRNA expression were detected by reverse transcription-quantitative polymerase chain reaction assay in carcinoma and non-carcinoma tissues from 75 patients, while the protein expression levels were evaluated by immunohistochemistry and western blotting. Additional associations between DCP1a expression and clinical characteristics were analyzed by χ test and Cox regression analysis. In the 75 cases, the levels of DCP1a mRNA and protein expression were increased in colorectal carcinoma tissues compared with non-carcinoma tissues. A high expression of DCP1a was significantly associated with lower survival rates in patients with CRC compared with patients with low DCP1a expression (P=0.001). Associations with depth of invasion (P=0.008), lymph node metastasis (P=0.001) and tumor node metastasis stage (P=0.001) were also observed. Additional Cox regression analysis revealed that the DCP1a expression (P=0.012) is an independent factor in survival rate. It was also identified that DCP1a may have high expression in colorectal carcinoma tissues and be associated with poor prognosis. This suggests that DCP1a may be a diagnostic marker or prognostic indicator to assist with patient assessments and therapies.

Citing Articles

Aptamer-based assay for high-throughput substrate profiling of RNA decapping enzymes.

Grab K, Fido M, Spiewla T, Warminski M, Jemielity J, Kowalska J Nucleic Acids Res. 2024; 52(21):e100.

PMID: 39445825 PMC: 11602136. DOI: 10.1093/nar/gkae919.

YAP/TAZ enhances P-body formation to promote tumorigenesis.

Shen X, Peng X, Guo Y, Dai Z, Cui L, Yu W Elife. 2024; 12.

PMID: 39046443 PMC: 11268890. DOI: 10.7554/eLife.88573.

Energy stress promotes P-bodies formation via lysine-63-linked polyubiquitination of HAX1.

Zhan W, Li Z, Zhang J, Liu Y, Liu G, Li B EMBO J. 2024; 43(13):2759-2788.

PMID: 38769438 PMC: 11217408. DOI: 10.1038/s44318-024-00120-6.

LncRNA regulates axis to promote the progression of non-small cell lung cancer.

Zhang Y, Ma H J Thorac Dis. 2023; 15(3):1289-1301.

PMID: 37065560 PMC: 10089871. DOI: 10.21037/jtd-23-153.

A Poxvirus Decapping Enzyme Colocalizes with Mitochondria To Regulate RNA Metabolism and Translation and Promote Viral Replication.

Cao S, Molina J, Cantu F, Hernandez C, Yang Z mBio. 2022; 13(3):e0030022.

PMID: 35435699 PMC: 9239241. DOI: 10.1128/mbio.00300-22.

References

Eulalio A, Behm-Ansmant I, Schweizer D, Izaurralde E . P-body formation is a consequence, not the cause, of RNA-mediated gene silencing. Mol Cell Biol. 2007; 27(11):3970-81. PMC: 1900022. DOI: 10.1128/MCB.00128-07. View

Yalamati P, Bhongir A, Karra M, Beedu S . Comparative Analysis of Urinary Total Proteins by Bicinchoninic Acid and Pyrogallol Red Molybdate Methods. J Clin Diagn Res. 2015; 9(8):BC01-4. PMC: 4576529. DOI: 10.7860/JCDR/2015/13543.6313. View

Cougot N, Daguenet E, Baguet A, Cavalier A, Thomas D, Bellaud P . Overexpression of MLN51 triggers P-body disassembly and formation of a new type of RNA granules. J Cell Sci. 2014; 127(Pt 21):4692-701. DOI: 10.1242/jcs.154500. View

Feroci F, Fong Y . Use of clinical score to stage and predict outcome of hepatic resection of metastatic colorectal cancer. J Surg Oncol. 2010; 102(8):914-21. DOI: 10.1002/jso.21715. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Ross J . Control of messenger RNA stability in higher eukaryotes. Trends Genet. 1996; 12(5):171-5. DOI: 10.1016/0168-9525(96)10016-0. View

Siegel R, DeSantis C, Jemal A . Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014; 64(2):104-17. DOI: 10.3322/caac.21220. View

Aizer A, Kafri P, Kalo A, Shav-Tal Y . The P body protein Dcp1a is hyper-phosphorylated during mitosis. PLoS One. 2013; 8(1):e49783. PMC: 3534667. DOI: 10.1371/journal.pone.0049783. View

Arribas-Layton M, Wu D, Lykke-Andersen J, Song H . Structural and functional control of the eukaryotic mRNA decapping machinery. Biochim Biophys Acta. 2013; 1829(6-7):580-9. PMC: 3660425. DOI: 10.1016/j.bbagrm.2012.12.006. View

10.

Hayes J, Peruzzi P, Lawler S . MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014; 20(8):460-9. DOI: 10.1016/j.molmed.2014.06.005. View

11.

Zhang W, Liu H, Yin J, Wu W, Zhu D, Amos C . Genetic variants in the PIWI-piRNA pathway gene DCP1A predict melanoma disease-specific survival. Int J Cancer. 2016; 139(12):2730-2737. PMC: 5282969. DOI: 10.1002/ijc.30409. View

12.

Vallazza B, Petri S, Poleganov M, Eberle F, Kuhn A, Sahin U . Recombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyond. Wiley Interdiscip Rev RNA. 2015; 6(5):471-99. DOI: 10.1002/wrna.1288. View

13.

Franks T, Lykke-Andersen J . The control of mRNA decapping and P-body formation. Mol Cell. 2008; 32(5):605-15. PMC: 2630519. DOI: 10.1016/j.molcel.2008.11.001. View

14.

Chen V, Hsieh M, Charlton M, Ruiz B, Karlitz J, Altekruse S . Analysis of stage and clinical/prognostic factors for colon and rectal cancer from SEER registries: AJCC and collaborative stage data collection system. Cancer. 2014; 120 Suppl 23:3793-806. PMC: 4239669. DOI: 10.1002/cncr.29056. View

15.

Shimamoto Y, Nukatsuka M, Takechi T, Fukushima M . Association between mRNA expression of chemotherapy-related genes and clinicopathological features in colorectal cancer: A large-scale population analysis. Int J Mol Med. 2015; 37(2):319-28. PMC: 4716796. DOI: 10.3892/ijmm.2015.2427. View

16.

Beelman C, Parker R . Degradation of mRNA in eukaryotes. Cell. 1995; 81(2):179-83. DOI: 10.1016/0092-8674(95)90326-7. View

17.

Chen W, Zheng R, Baade P, Zhang S, Zeng H, Bray F . Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66(2):115-32. DOI: 10.3322/caac.21338. View

18.

Polunovsky V, Bitterman P . The cap-dependent translation apparatus integrates and amplifies cancer pathways. RNA Biol. 2006; 3(1):10-7. DOI: 10.4161/rna.3.1.2718. View

19.

Center M, Jemal A, Smith R, Ward E . Worldwide variations in colorectal cancer. CA Cancer J Clin. 2009; 59(6):366-78. DOI: 10.3322/caac.20038. View

20.

Anderson P, Kedersha N, Ivanov P . Stress granules, P-bodies and cancer. Biochim Biophys Acta. 2014; 1849(7):861-70. PMC: 4457708. DOI: 10.1016/j.bbagrm.2014.11.009. View